212 related articles for article (PubMed ID: 18055512)
1. Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats.
Sun X; Ku DD
Am J Physiol Heart Circ Physiol; 2008 Feb; 294(2):H801-9. PubMed ID: 18055512
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
Li XL; Guan RJ; Li JJ
J Cardiovasc Pharmacol; 2012 Aug; 60(2):219-26. PubMed ID: 22592772
[TBL] [Abstract][Full Text] [Related]
3. Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat.
DeMarco VG; Habibi J; Whaley-Connell AT; Schneider RI; Sowers JR; Andresen BT; Gutweiler AA; Ma L; Johnson MS; Ferrario CM; Dellsperger KC
Am J Physiol Heart Circ Physiol; 2009 Sep; 297(3):H1128-39. PubMed ID: 19633211
[TBL] [Abstract][Full Text] [Related]
4. Allicin in garlic protects against coronary endothelial dysfunction and right heart hypertrophy in pulmonary hypertensive rats.
Sun X; Ku DD
Am J Physiol Heart Circ Physiol; 2006 Nov; 291(5):H2431-8. PubMed ID: 16731642
[TBL] [Abstract][Full Text] [Related]
5. The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.
Guerard P; Rakotoniaina Z; Goirand F; Rochette L; Dumas M; Lirussi F; Bardou M
Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):401-14. PubMed ID: 16896805
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism.
Pei Y; Ma P; Wang X; Zhang W; Zhang X; Zheng P; Yan L; Xu Q; Dai G
Eur J Pharmacol; 2011 Sep; 666(1-3):165-72. PubMed ID: 21641341
[TBL] [Abstract][Full Text] [Related]
7. Selective right, but not left, coronary endothelial dysfunction precedes development of pulmonary hypertension and right heart hypertrophy in rats.
Sun X; Ku DD
Am J Physiol Heart Circ Physiol; 2006 Feb; 290(2):H758-64. PubMed ID: 16172159
[TBL] [Abstract][Full Text] [Related]
8. Single-dose rosuvastatin ameliorates lung ischemia-reperfusion injury via upregulation of endothelial nitric oxide synthase and inhibition of macrophage infiltration in rats with pulmonary hypertension.
Matsuo S; Saiki Y; Adachi O; Kawamoto S; Fukushige S; Horii A; Saiki Y
J Thorac Cardiovasc Surg; 2015 Mar; 149(3):902-9. PubMed ID: 25454916
[TBL] [Abstract][Full Text] [Related]
9. Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension.
Umar S; de Visser YP; Steendijk P; Schutte CI; Laghmani el H; Wagenaar GT; Bax WH; Mantikou E; Pijnappels DA; Atsma DE; Schalij MJ; van der Wall EE; van der Laarse A
Am J Physiol Heart Circ Physiol; 2009 Nov; 297(5):H1606-16. PubMed ID: 19783775
[TBL] [Abstract][Full Text] [Related]
10. [Effects of rosuvastatin on monocrotaline-induced pulmonary artery hypertension in rats].
Li XL; Guan RJ; Xu QH; Wu ZY
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Mar; 39(3):247-53. PubMed ID: 21609531
[TBL] [Abstract][Full Text] [Related]
11. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.
Liu CP; Dai ZK; Huang CH; Yeh JL; Wu BN; Wu JR; Chen IJ
Kaohsiung J Med Sci; 2014 Jun; 30(6):267-78. PubMed ID: 24835346
[TBL] [Abstract][Full Text] [Related]
12. Total ginsenosides inhibit the right ventricular hypertrophy induced by monocrotaline in rats.
Qin N; Gong QH; Wei LW; Wu Q; Huang XN
Biol Pharm Bull; 2008 Aug; 31(8):1530-5. PubMed ID: 18670084
[TBL] [Abstract][Full Text] [Related]
13. HMG-CoA reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via down-regulation of caveolin-1 and activation of endothelial nitric oxide synthase.
Suh JW; Choi DJ; Chang HJ; Cho YS; Youn TJ; Chae IH; Kim KI; Kim CH; Kim HS; Oh BH; Park YB
J Korean Med Sci; 2010 Jan; 25(1):16-23. PubMed ID: 20052342
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin attenuates the elevation in blood pressure induced by overexpression of human C-reactive protein.
Li X; Yang G; Zhao G; Wu B; Edin ML; Zeldin DC; Wang DW
Hypertens Res; 2011 Jul; 34(7):869-75. PubMed ID: 21562509
[TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat.
Jasińska-Stroschein M; Owczarek J; Wesołowska A; Orszulak-Michalak D
Acta Pharm; 2014 Sep; 64(3):345-53. PubMed ID: 25296680
[TBL] [Abstract][Full Text] [Related]
16. Preventive treatment with atorvastatin ameliorates endothelial dysfunction of small pulmonary arteries in monocrotaline-induced pulmonary hypertensive rats.
Lin Z; Jiang Z; Huang X; Cai X; Wang H; Xie L
Clin Exp Hypertens; 2017; 39(6):495-501. PubMed ID: 28628347
[TBL] [Abstract][Full Text] [Related]
17. Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension.
Homma N; Morio Y; Takahashi H; Yamamoto A; Suzuki T; Sato K; Muramatsu M; Fukuchi Y
Respiration; 2006; 73(1):105-12. PubMed ID: 16432296
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats.
Habibi J; Whaley-Connell A; Qazi MA; Hayden MR; Cooper SA; Tramontano A; Thyfault J; Stump C; Ferrario C; Muniyappa R; Sowers JR
Endocrinology; 2007 May; 148(5):2181-8. PubMed ID: 17317778
[TBL] [Abstract][Full Text] [Related]
19. HMG-COA reductase inhibitors: An opportunity for the improvement of imatinib safety. An experimental study in rat pulmonary hypertension.
Jasińska-Stroschein M; Owczarek J; Surowiecka A; Kącikowska J; Orszulak-Michalak D
Pharmacol Rep; 2015 Feb; 67(1):32-7. PubMed ID: 25560572
[TBL] [Abstract][Full Text] [Related]
20. Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats.
Tofovic SP; Salah EM; Mady HH; Jackson EK; Melhem MF
J Cardiovasc Pharmacol; 2005 Oct; 46(4):430-7. PubMed ID: 16160593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
